Regeneron Pharmaceuticals, Inc. (REGN) disclosed on Monday that the FDA has issued Complete Response Letters, rejecting the approval of the Biologics License Application for Odronextamab in relapsed/refractory follicular lymphoma and in R/R diffuse large B-cell lymphoma after two or more lines of systemic therapy.
This decision was made due to an issue concerning the enrollment status of the confirmatory trials.
Regeneron intends to share updates on enrollment and regulatory timelines later this year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.